AD and psoriasis were once thought to be opposites in terms of immune response, with AD linked to a Th2-dominant pathway and ...

The franchise drug for autoimmune disorders such as dermatitis could face a challenger: A candidate from Apogee Therapeutics.

Apogee Therapeutics, Inc.'s APG777 shows promising week-16 efficacy and dosing potential, targeting the AT market. Click for ...

Patients with asthma and allergic bronchopulmonary aspergillosis experienced improvements with dupilumab, according to data presented at the American Thoracic Society International Conference.Quality ...

Shares of US clinical-stage biotech Apogee Therapeutics closed down 17.3% at $39.24 yesterday, despite announcing positive 16 ...

Some two dozen biotech developers of PROTACs, molecular glues and other types of protein-degrading drugs have sprung up over ...

Barclays (LON: BARC) has initiated coverage on Galderma Group AG (SIX: GALD) and Zealand Pharma (NASDAQ: ZEAL) with Overweight ratings, citing distinct growth dri ...

Dupixent (dupilumab) achieved a five-fold greater sustained remission rate at 36 weeks than placebo in the study – 20% versus 4% – meaning that the skin lesions had been resolved, with no ...

Dupixent (dupilumab) – an inhibitor of interleukins 4 and 13 – has been given a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) as an add-on therapy for chronic ...

GlobeNewswire Jun 24, 2025, 4:30:00 AM Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP) GlobeNewswire Jun 19, 2025, 10:00:53 PM ...

See the latest Sanofi SA ADR stock price (SNY:XNAS), related news, valuation, dividends and more to help you make your investing decisions.

Eating gluten may worsen eczema symptoms in people with a gluten-related disorder, such as celiac disease. However, more research is needed to fully understand the link between gluten and eczema ...